An observational study in Superficial Esophageal Cancer, Oesophageal Adenocarcinoma and Oesophageal Squamous Cell Carcinoma, sponsored by Société Française d'Endoscopie Digestive. Recruiting at 7 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Société Française d'Endoscopie Digestive · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Adenocarcinoma Of Esophagus with a site in France — 12 open to participants now, 18 under way, 5 of them phase 3. Adenocarcinoma Of Esophagus · France.
Among the 36 studies in Adenocarcinoma Of Esophagus with a site in France, this one is one of 5 that started in 2026, is one of 4 observational ones, reaches primary completion later than 17 of the 17 other live ones, and was the 33rd registered.
354 studies on the registry are indexed under Adenocarcinoma Of Esophagus; 80 are open to participants now.
Browse Adenocarcinoma Of Esophagus studies →12 of the 36 studies in Adenocarcinoma Of Esophagus with a site in France are open now. Recruiting first, the newest first:
Pfizer · Sites in France, United States, Canada and 7 more countries
Ages 18+
Bristol-Myers Squibb · Sites in France, United States, Argentina and 17 more countries
Ages 18+
AstraZeneca · Sites in France, United States, Australia and 21 more countries
Ages 18+
UNICANCER · Sites in France
Ages 18+
University Hospital, Antwerp · Sites in France, Belgium, Denmark and 3 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 70 Adenocarcinoma Of Esophagus studies recruiting now, 60 (86%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 13
First in 1996; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 750 is above the median of 200 across 47 observational studies indexed under Adenocarcinoma Of Esophagus.
Median enrollment 282 across the 32 interventional studies, 479 across the 4 observational. Of the 14 that completed or were terminated, 2 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 36 have an industry lead sponsor. The 10 most frequent:
Société Française d'Endoscopie Digestive is the lead sponsor of 25 studies on the registry; 5 are open to participants now.
Société Française d'Endoscopie Digestive has 1 study filed under Adenocarcinoma Of Esophagus — fewer than ten, so there is no comparison to draw.
3 of the studies in Adenocarcinoma Of Esophagus with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05476796UNICANCEROxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer | 2026-12 |
| NCT04389632Seagen, a wholly owned subsidiary of PfizerA Study of Sigvotatug Vedotin in Advanced Solid Tumors | 2027-06-16 |
| NCT06846346UNICANCERTesting Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies in Adenocarcinoma Of Esophagus with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In France in 2018, there were an estimated 2,074 new cases of esophageal adenocarcinoma and 3,224 cases of squamous cell carcinoma. The estimated deaths from esophageal cancer were 3,725, with a standardized 5-year net survival rate of 20% for cases diagnosed between 2010 and 2015, mainly due to late diagnosis.
Surgery was historically the standard treatment for localized disease but carries significant morbidity. Over the past decade, endoscopic treatments, particularly endoscopic submucosal dissection (ESD), have become the reference approach for superficial esophageal cancers.
After endoscopic resection, histological analysis allows classification of recurrence risk into very low, low, and high categories. Predicting lymph node or distant recurrence is complex, depending on factors such as depth of wall infiltration, lymphovascular invasion, and tumor differentiation. The frequent combination of unfavorable histological features may have led to an overestimation of lymph node involvement risk in T1b cancers.
ESD is widely performed in France, with over 1,600 procedures reported in 2023 for esophageal and gastric lesions, demonstrating the feasibility of a large observational study.
This multicenter French cohort will evaluate technical, oncological, and organizational outcomes of esophageal ESD, including overall survival, recurrence-free survival, and management of residual Barrett's esophagus. It will also identify predictive factors for treatment success, recurrence, and complications, providing real-world evidence to guide patient management.
Eligible patients include all individuals referred to a participating center for endoscopic resection of an esophageal lesion and treated by submucosal dissection. This is a prospective, multicenter, observational study, conducted on an intention-to-treat basis. All consecutive patients referred for esophageal ESD will be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Recurrence-free survival according to adjuvant treatment
Recurrence-free survival will be evaluated in patients after endoscopic submucosal dissection (ESD) of superficial esophageal carcinoma. Patients may receive adjuvant therapy (surgery, chemotherapy, or chemoradiotherapy) at the treating physician's discretion. Recurrence includes local, regional, or metastatic relapse as defined by clinical, endoscopic, and imaging criteria and validated by multidisciplinary team discussion. Recurrence will be monitored throughout the 5-year follow-up period to compare outcomes between patients receiving adjuvant therapy versus surveillance.
Time frame: From enrollment to 5 years
R0 resection rate
Proportion of patients with tumor-free lateral and deep margins confirmed by histopathology.
Time frame: From ESD to 5 years
En bloc resection rate
Proportion of lesions resected in a single piece exclusively by ESD.
Time frame: From ESD to 5 years
Curative resection rate
Proportion of R0 resections meeting favorable histological criteria: no lymphovascular invasion, no tumor budding, well-differentiated tumor, submucosal invasion \<200 µm (squamous cell carcinoma) or \<500 µm (adenocarcinoma).
Time frame: From ESD to 5 years
30-day complication rate
Rate of per- or post-procedural bleeding, immediate or delayed perforation, and strictures requiring endoscopic dilation.
Time frame: 30 days post-ESD
Rate of MDTB presentation
Proportion of patients whose management was discussed in a multidisciplinary team meeting.
Time frame: From ESD to 5 years
Concordance between MDTB decision and actual management
Proportion of patients for whom the implemented management matched the MDTB recommendation.
Time frame: From ESD to 5 years
Rate of patients receiving adjuvant treatment
Proportion of patients receiving any adjuvant therapy after ESD (surgery, radiotherapy, chemotherapy, immunotherapy, etc.).
Time frame: From enrollment to 5 years
Rate of complementary Barrett's eradication treatment (radiofrequency or other)
Proportion of patients treated for residual Barrett's esophagus using radiofrequency ablation or other endoscopic techniques.
Time frame: From ESD to 5 years
Morbidity of complementary treatments
Rate of complications related to adjuvant therapy or Barrett's treatment
Time frame: From ESD to 5 years
Efficacy of complementary treatments
Rate of complete remission of intestinal metaplasia or oncologic control following complementary tratmets
Time frame: From complementary treatment to 5 years
Prognostic factors for recurrence (local, regional, metastatic)
Identification of clinical, endoscopic, and histological variables associated with increased risk of recurrence, analyzed using univariate and multivariate methods.
Time frame: From enrollment to 5 years
Predictive factors for post-ESD complications
Analysis of factors associated with immediate or delayed complications (bleeding, perforation, stenosis) according to patient characteristics, ESD procedure, and adjuvant therapy.
Time frame: From ESD to 5 years
Predictive factors for R0 resection
Analysis of clinical, endoscopic, and procedural variables predictive of complete R0 resection.
Time frame: From ESD to 5 years
Diagnostic accuracy of optical endoscopic classifications vs. histology
Accuracy of endoscopic optical classifications in predicting histology prior to resection, compared to histopathology results.
Time frame: From ESD to pathology report
Impact of center volume on outcomes
Evaluation of the influence of annual ESD procedure volume in a center on technical and oncologic outcomes
Time frame: From enrollment to 5 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2031, 68 months after the start.
Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Mar 2026, on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Société Française d'Endoscopie Digestive